Acquisitions, Investments and Licenses - Schedule of Pro Forma (Details) - Transition Therapeutics - USD ($) $ in Thousands |
3 Months Ended | 9 Months Ended | ||
|---|---|---|---|---|
Sep. 30, 2016 |
Sep. 30, 2015 |
Sep. 30, 2016 |
Sep. 30, 2015 |
|
| Business Acquisition [Line Items] | ||||
| Revenues | $ 298,035 | $ 143,034 | $ 946,172 | $ 215,547 |
| Net income (loss) | (16,897) | 124,942 | (18,147) | (51,089) |
| Net income (loss) attributable to common shareholders | $ (16,897) | $ 124,942 | $ (18,147) | $ (49,689) |
| X | ||||||||||
- Definition Business Acquisition, Pro Forma Net Income (Loss) Available to Common Stockholders No definition available.
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. No definition available.
|
| X | ||||||||||
- Definition The pro forma net Income or Loss for the period as if the business combination or combinations had been completed at the beginning of a period. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition The pro forma revenue for a period as if the business combination or combinations had been completed at the beginning of the period. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Details
|